Veloxis Restructures to Focus on Late-Stage Once-Daily Immunosuppressant - Genetic Engineering News

Apart from LCP-Tacro, the firm’s clinical pipeline includes the Phase II- and III-ready cardiovascular products AtorFen™, a fixed-dose combination tablet of fenofibrate and atorvastatin, and LCP-Feno™, a generic fenofibrate tablet formulation.

Expect strong growth from US in FY13-14: Lupin - MoneyControl.com

A: Firstly on Antara, the fenofibrate market in America was declining. To that extent, Antara also saw a decline. But the decline was itself much lower than the market decline in Fenofibrate as a category. When it comes to the direct-to-market ...

Abbott: New Reasons The Split Could Tank Stock - Seekingalpha.com

Fenofibrate, sold as Trilipix and Tricor, is the next biggest product, with sales of $329 million, but sales have fallen by 11%, year over year. Androgel is the newest high flyer, with "low-T" being the latest over-hyped bugaboo to bedevil aging baby boomers.

Santarus Announces Presentation of UCERIS Phase III Extended Use Data at Digestive Disease Week Meeting - Marketwatch

(fenofibrate) tablets, which is indicated as an adjunct to diet to reduce high cholesterol. Santarus has a diverse product development pipeline. A New Drug Application for UCERIS(TM) (budesonide) 9 mg tablets for induction of remission of mild ...

Lupin to focus on new product infusion in FY13 - MoneyControl.com

Antara, the Fenofibrate market as such, degrew by about 18%. Our brand degrew by about 6%. Having said that, the prescriptions of Antara grew by about 3% and to me, that’s a positive mark because while the market is degrowing and there is a ...

Santarus' CEO Presents at Bank of America Merrill Lynch 2012 Health Care Conference (Transcript) - Seekingalpha.com

This is of course fenofibrate, it’s a low dose version of fenofibrate and of course indicated for the treatment of hypertriglyceridemia as well as mixed dyslipidemia. And you are well aware, the high overlap of co-morbidity and obesity and cardiovascular ...